Envista (NVST) to Release Earnings on Thursday

Envista (NYSE:NVST - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, July 31st. Analysts expect Envista to post earnings of $0.24 per share and revenue of $638.21 million for the quarter. Envista has set its FY 2025 guidance at 0.950-1.050 EPS.

Envista (NYSE:NVST - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. The business had revenue of $616.90 million during the quarter, compared to analysts' expectations of $608.17 million. Envista had a negative net margin of 44.90% and a positive return on equity of 4.07%. The firm's revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share. On average, analysts expect Envista to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Envista Stock Up 0.7%

Shares of NYSE:NVST traded up $0.14 during midday trading on Friday, reaching $20.81. The company had a trading volume of 2,267,160 shares, compared to its average volume of 1,861,461. The stock has a market cap of $3.53 billion, a PE ratio of -3.19, a P/E/G ratio of 1.31 and a beta of 1.00. Envista has a 1-year low of $14.22 and a 1-year high of $23.00. The business's 50 day moving average price is $19.11 and its 200 day moving average price is $18.57. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NVST. Bank of America lowered their price objective on shares of Envista from $26.00 to $23.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Baird R W raised Envista from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 27th. Morgan Stanley set a $16.00 price objective on shares of Envista in a research report on Tuesday, April 15th. UBS Group lowered their target price on shares of Envista from $21.00 to $18.00 and set a "neutral" rating on the stock in a report on Monday, May 5th. Finally, Evercore ISI increased their target price on Envista from $19.00 to $23.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. One analyst has rated the stock with a sell rating, nine have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $20.23.

Hedge Funds Weigh In On Envista

A number of hedge funds have recently bought and sold shares of NVST. Goldman Sachs Group Inc. grew its position in shares of Envista by 39.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company's stock worth $10,859,000 after buying an additional 177,630 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Envista by 15.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company's stock worth $9,821,000 after purchasing an additional 76,246 shares in the last quarter. Millennium Management LLC increased its position in Envista by 218.6% in the 1st quarter. Millennium Management LLC now owns 383,966 shares of the company's stock valued at $6,627,000 after buying an additional 263,442 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in Envista by 26.6% during the 1st quarter. Royal Bank of Canada now owns 23,240 shares of the company's stock worth $401,000 after buying an additional 4,885 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.